A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2018
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Amgen
- 23 May 2018 Planned End Date changed from 13 Sep 2018 to 30 Nov 2018.
- 23 May 2018 Planned primary completion date changed from 13 Sep 2018 to 30 Nov 2018.
- 07 Mar 2018 Status changed from not yet recruiting to recruiting.